Weekly Recap | Bristol Myers Squibb +2.9%, breast cancer Phase 3 cut risk by 59%Weekly Review·Oct 24, 2026 at 06:01 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb +1.07%, multiple Phase 3 winsWeekly Review·Oct 17, 2026 at 06:46 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb -3.32%, consensus target above spotWeekly Review·Oct 10, 2026 at 06:13 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb this week, a quiet, range-bound stretchWeekly Review·Oct 3, 2026 at 06:25 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb -0.32%, FDA clears ZENBEXUSWeekly Review·Sep 26, 2026 at 06:02 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb -0.91%, consensus target above spotWeekly Review·Sep 19, 2026 at 05:46 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb -4.76%, positive CAR-T data but studies pausedWeekly Review·Sep 12, 2026 at 07:50 AMBMY-2.41%
Weekly Recap | Bristol Myers Squibb +0.36%, CAR-T trial pauses in focusWeekly Review·Sep 5, 2026 at 06:16 AMBMY-2.41%
